Abstract: The aim of this study was to formulate and evaluate floating tablets using Nimesulide as a model drug. Nimesulide Floating tablets were prepared by wet granulation method using polymers (HPMC K4M, HPMC K15M, and Carbapol 934P) by changing drug to polymer ratio as 1:1, 1:1.5, and 1:2. Sodium bicarbonate and citric acid used as generating agents. Lactose used as diluents and PVP K30 used as granulating agent with isopropyl alcohol as solvent. The granules formulated and evaluated for flow properties, and the prepared into tablets and evaluated for physical properties, invitro buoyancy studies, drug content. All the formulations showed the values within the prescribed limit, which indicates that the prepared tablets are of standard quality. It was observed that the gas generated is trapped and protected within the gel, formed by the polymers, thus decreasing the density of the tablet below 1 and tablet becomes buoyant. In the formulations F1 to F6, it was observed that decreasing Floating lag time and the increasing Total floating time as the polymer to drug ratio increases. The higher rate and extent drug release was observed from the formulations prepared by 1:1 ratio (i.e. F1, F4, and F7). The percentage of drug release was less from F7, F8, F9 formulations prepared by Carbopol, due to its high viscosity and less permeability towards water. The prepared tablets were evaluated for uniformity hardness, friability, drug content, in vitro buoyancy studies; dissolution studies the invitro release data were fitted to different kinetic models. The drug release follows Zero order with \( R^2 \) value 0.999.

Key words: Bulk density, Carr’s index, Floating tablets, Formulations, Hausners ratio, Wet granulation

1. INTRODUCTION

Oral route is the most convenient and extensively used route for drug administration. This route has high uncomplaining adequacy, due to painless of supervision. Oral route of supervision has been received more attention in the pharmaceutical field because of the more flexibility in the designing of dosage form than drug delivery design for other routes. Most of the oral controlled drug delivery systems rely on diffusion, dissolution or combination of both mechanisms, to release the drug in a controlled manner to the Gastrointestinal Tract (GIT) and the drug profile data, such as dose, absorption properties and the quantity of drug needed, one can determine the desired release rate of the drug from controlled release dosage form. Drugs that are easily absorbed from the G.I.T and having a short half-life are eliminated quickly from the blood circulation. To avoid this problem the oral controlled release formulations have been developed, as these will release the drug slowly into the GIT and maintain a constant drug concentration in the serum for a longer period of time. More than 50% of drug delivery systems available in the market are oral drug delivery systems. These systems have the obvious advantages of case of administration and patient acceptance. One would always like to have ideal drug delivery systems that will possess two main properties: It will be a single dose for the whole duration of treatment and It will deliver the active drug directly at the site of action. gastro retentive systems. Furthermore, some drugs, such as Isosorbide dinitrate, that are absorbed equally well throughout the GI tract will not benefit from incorporation into a gastric retention system. Certain types of drugs can benefit from using gastro retentive devices. These include drugs that act locally in the stomach, are primarily absorbed in the stomach; are poorly soluble at an alkaline pH, have a narrow window of absorption, and degrade in the colon. The goal of any drug delivery system is to provide a therapeutic amount of drug to the proper site of the body, to achieve promptly and then maintain the desired therapeutic drug concentration that elicits the pharmacological action and to minimize the incidence and the severity of unwanted adverse effects. To achieve this goal, it would be advantageous and more convenient to maintain a dosing frequency to once, or at most, a twice-daily regimen. An appropriately designed extended release dosage form can be a major advance in this direction.
1.1 Basic Gastrointestinal tract physiology:

It is well renowned that inclination may be used as storage area for sustained-release (SR) dosage forms, both in human and veterinary applications. The stomach is anatomically divided into three parts: fondues, body, and antrum\(^1\) (pylorus). The proximal part made of fundus and body acts as a reservoir for undigested material, whereas the antrum is the main site for mixing motions and act as a pump to accomplish gastric emptying. The process of gastric emptying occurs during fasting as well as fed states; however, the pattern of motility differs markedly in two states. In the fasted states, it is characterized by an interdigestive series of electrical events, which cycle both through stomach and intestine every 2 to 3 hours. This is called the interdigestive myoelectric cycle or migrating myoelectric cycle (MMC).

2. MATERIALS AND METHODS

**Materials:** Nimesulide, Carbopol 934P, Hydroxy propyl methyl cellulose (K4M, K15M), polyvinylpyrrolidone, Magnesium stearate, Iso propyl alcohol, Lactose, Hydrochloric\(^5\) acid, Talc, citric acid and gas generating agent such as sodium bicarbonate were used as other ingredients. All the materials used in experimental works were obtained from S.D Fine chemicals, Hyderabad, India. All reagents used were of analytical grade.

**Methods:** Nimesulide Floating tablets\(^2\) were prepared by wet granulation method using polymers (HPMC K4M, HPMC K15M, and Carbopol 934P) by changing drug to polymer ratio as 1:1, 1:1.5, and 1:2. Sodium bicarbonate and citric acid used as generating agents. Lactose used as diluents and PVP K30 used as granulating agent with isopropyl alcohol as solvent. Nimesulide and all other ingredients were weighed separately and passed through sieve no. 25. The active ingredient, HPMC(K4M, K15M), polyvinylpyrrolidone and 50% of the lubricants were mixed together. The mixture was then compacted in a slugging\(^3\) machine to form the compacts. The compacts were then milled and passed through sieve no. 18 followed by sieve no. 60. The particles that retained on sieve no. 60 were taken as granules and those passing through the sieve were fines. The fines were again compacted, milled and sieved through sieve no. 18 and 60. The cycle of compaction- milling- sieving was repeated until the granules and fines were obtained in the ratio of about 60:20. The granules and fines were then mixed together and the remaining ingredients except magnesium stearate were added to it and mixed. The remaining lubricant i.e. magnesium stearate was then added and mixed to the above mixture to form the final blend. The final blend was compressed into tablets using single punch tablet rotary press\(^4\).

3. EVALUATION OF FLOATING TABLETS

3.1. Evaluation of Flow Properties of granules before compression:

**Angle of repose (\(\theta\)):**

The angle of repose of granules was determined by the funnel method. The accurately weighed granules were taken in a funnel. The height of the funnel was adjusted in such a way that the tip of the funnel just touched the apex of the heap of the granules. The granules were allowed to flow through the funnel freely onto the surface. The diameter of the powder cone was measured and angle of repose was calculated using the following equation. 

\[
\tan \theta = \frac{h}{r} \quad \text{Where, } h \text{ and } r \text{ are the height and radius of the powder cone respectively.}
\]

**Fig 1: measuring angle of repose**

**Bulk density:**

Both loose bulk density (LBD) and tapped bulk density (TBD) were determined. A quantity of 2gm of powder from each formula, previously lightly shaken to break any agglomerates formed, was introduced into a 10-ml measuring cylinder. After the initial volume was observed, the cylinder was allowed to fall under its own weight onto a hard surface from the height of 2.5 cm at 2-second intervals. The tapping was continued until no further change in volume was noted. LBD and TBD were calculated using the following formulas:

\[
\text{LBD} = \frac{\text{weight of the powder}}{\text{volume of the packing}}
\]

\[
\text{TBD} = \frac{\text{weight of the powder}}{\text{tapped volume of the packing}}
\]

\[
\text{Carr’s index (\%)} = \left(\frac{\text{TBD} - \text{LBD}}{\text{LBD}}\right) \times 100
\]

\[
\text{Haussler’s ratio} = \frac{\text{TBD}}{\text{LBD}}
\]

Where, TBD - Tapped Bulk Densities, LBD - Loose Bulk Density

3.2. Evaluation of tablets after compression:

**Size of the floating tablets:** The thickness and Diameter of each tablet is measured by using vernier calipers. It is measured in mm.

**Uniformity of Weight:**

Twenty tablets were prepared in each formulation, weighed individually to check for weight variation. IP limit for weight variation in case of tablets.

Hardness: The hardness of the tablet was determined using a Monsanto hardness tester. It is expressed in Kg / cm²

Friability:

After four minutes of this treatment or 100 revolutions, the tablets are weighed and the weight compared with the initial weight. The loss due to abrasion is a measure of the tablet friability. The value is expressed as a percentage (%).

Drug content:

Tablet containing 40mg of active ingredient (drug) is dissolved in 100ml of 0.1 Hcl (solvent) in volumetric flask and make up to mark. The drug is allowed to dissolve in the solvent. The solution is filtered; 1ml of the filtrate was taken in 50ml of volumetric flask and makes it up to mark with the solvent. The prepared solution was analyzed spectrophotometrically. The content of medicament is expressed in percentage (%)

3.3. Buoyancy studies: The time required for the tablet to rise to the surface and float was determined as Floating lag time. The duration of time the dosage form constantly remained on the surface of medium was determined as the Total floating time. The in vitro floating behavior of the tablets was studied by placing them in 900 ml of plastic containers filled with 500 ml of 0.1 N HCl (pH 1.2, 37.5°C). The floating lag times and floating durations of the tablets were determined by visual observation

![Image](image1.png)

![Image](image2.png)

Fig.2: Floating tablet in 0.1N Hcl showing floating lag time

4. RESULTS AND DISCUSSION

4.1. Results of Pre compression Flow Properties of Granules of Nimesulide:

Table 1. Invitro buoyancy studies for prepared tablets:

<table>
<thead>
<tr>
<th>S.no</th>
<th>Formulation code</th>
<th>Buoyancy Lag Time (Sec)</th>
<th>Total Floating Time (Hrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F1</td>
<td>46</td>
<td>&gt;5</td>
</tr>
<tr>
<td>2</td>
<td>F2</td>
<td>33</td>
<td>&gt;5.5</td>
</tr>
<tr>
<td>3</td>
<td>F3</td>
<td>20</td>
<td>&gt;6</td>
</tr>
<tr>
<td>4</td>
<td>F4</td>
<td>80</td>
<td>&gt;3.5</td>
</tr>
<tr>
<td>5</td>
<td>F5</td>
<td>67</td>
<td>&gt;4</td>
</tr>
<tr>
<td>6</td>
<td>F6</td>
<td>51</td>
<td>&gt;5</td>
</tr>
<tr>
<td>7</td>
<td>F7</td>
<td>132</td>
<td>&gt;3.5</td>
</tr>
<tr>
<td>8</td>
<td>F8</td>
<td>120</td>
<td>&gt;3.5</td>
</tr>
<tr>
<td>9</td>
<td>F9</td>
<td>94</td>
<td>&gt;4</td>
</tr>
</tbody>
</table>

Table 4. Calculation of cumulative percentage of drug release for different formulations

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Cumulative drug release of F1 (%)</th>
<th>Cumulative drug release of F2 (%)</th>
<th>Cumulative drug release of F3 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>30</td>
<td>9.9</td>
<td>8.1</td>
<td>7.1</td>
</tr>
<tr>
<td>60</td>
<td>18.4</td>
<td>19.8</td>
<td>19.5</td>
</tr>
<tr>
<td>90</td>
<td>35.4</td>
<td>32.5</td>
<td>29.7</td>
</tr>
<tr>
<td>120</td>
<td>47.89</td>
<td>41.85</td>
<td>39.6</td>
</tr>
<tr>
<td>150</td>
<td>58.99</td>
<td>53.4</td>
<td>48.3</td>
</tr>
<tr>
<td>180</td>
<td>72.5</td>
<td>65.3</td>
<td>58.2</td>
</tr>
<tr>
<td>210</td>
<td>83.6</td>
<td>76.05</td>
<td>66.3</td>
</tr>
<tr>
<td>240</td>
<td>92.25</td>
<td>82.95</td>
<td>76.7</td>
</tr>
</tbody>
</table>
Fig. 1: In vitro drug release for the formulations with polymer HPMC K4

Fig. 2: In vitro drug release for the formulations with polymer HPMC K15M

Fig. 3: In vitro drug release for the formulations with polymer Carbapol 934P

Fig. 4: In vitro drug release for different formulations

Fig. 5: Fitting of in vitro drug release in Zero order model for different formulations:

Fig. 6: Fitting of Zero order kinetics for formulation with HPMC K15M
Floating tablets were formulated and evaluated using Nimesulide as model drug (water-insoluble drug), HPMC K4M, HPMC K15M and Carbopol 934P use as polymers, by varying drug to polymer ratio as 1:1, 1:15, and 1:2.

All the formulations were prepared by using wet granulation method, where the concentration of the drug kept constant and concentration of polymers varied. PVP is used as a granulating agent. Lactose is used as a diluent and magnesium Stearate and talc were used as lubricant and glidant respectively. Sodium bicarbonate is used as gas generating agent. Citric acid is used to achieve buoyancy effect under the elevated pH, which results an enhancement in drug release.

The shapes of the tablets of all the formulations were found to be pale yellow, smooth, flat faced circular with no visible cracks.

The tablets prepared with low viscosity grade HPMC K4M (i.e. F1, F2, and F3) exhibited short Floating Lag Time and longer Floating Time, when compared with the formulations containing high viscous grade HPMC K15M (i.e. F4, F5, and F6), and Carbapol 934P (i.e. F7, F8, and F9).

It is concluded that the formulations prepared with low viscous HPMC K4M (F1, F2, and F3) showed desirable buoyancy time.

It is observed that, in all the formulations as the concentration of polymer increases, the amount of drug release was found to be decreased, because the amount of drug binded in the polymer could be more.

The percentage of drug release were found to be more with formulations prepared by 1:1 ratios (i.e. F1, F4 and
F7) where as in the case of formulations prepared with 1:2 ratios (i.e. F3, F6 and F9) the percentage of the drug release was found to be less.

It is observed that the percentage of drug release from the formulations prepared by Carbapol 934P (F7, F8, and F9) was found to be less, this may be due to its high viscosity and less permeability of water.

In-Vitro dissolution data was fitted to Zero order kinetics and First order kinetic models to check the release kinetics. The best fit release was achieved with Zero order kinetics.

6. REFERENCES


[3] Vishal G et al, have Formulated and Evaluated the Floating Tablets of Furosemide (F) by direct compression technique.


[5] D. B. Raju et al Formulated and evaluated the floating drug delivery system of Metformin Hydrochloride

[6] Kavita.K et al, have Formulated and Evaluated Floating Tablets of RHCL Using Natural and Synthetic Polymers

[7] Ravi Kumar et al, have Formulated and Evaluated of Effervescent Floating Tablets of Famotidine and designeGangadharappa et al, have Formulated and Evaluated in vitro studies of Gastric controlled release Floating Tablets of Atenolol using karaya gum and HPMC as matrix polymers. Atenolol floating tablets

[8] S.K.Sreekanthi et al , have Formulated and Evaluated studies of Floating Matrix tablets of Nifedipine using Hydroxypropyl methyl cellulose (HPMC K100M
